A consensus statement from the Society for Perioperative Assessment and Quality Improvement recommends patients should ...

Novo Nordisk's late stage diabetes candidate semaglutide ... in controlling glucose levels and body weight. The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-marketed ...

The newer generation of these medications, semaglutide (Ozempic and Rybelsus for T2D, Wegovy for weight reduction) and the dual GLP-1/ glucose-dependent insulinotropic polypeptide agonist ...

Ozempic (semaglutide) — The FDA approved Novo ... Sanofi’s injectable drug is indicated for Type 2 diabetes. Trulicity (dulaglutide) — The FDA approved the active ingredient in 2014, and ...

Older adults taking GLP-1 receptor agonists, primarily semaglutide (Rybelsus, Ozempic, Wegovy), had a small uptick in their ...

Share on Pinterest Ozempic, the active ingredient of which is semaglutide, can also reduce the risk of heart disease, according to research. Steve Christo – Corbis/Corbis via Getty Images ...

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of semaglutide highlighted in a letter published in the JAMA Cardiology. The letter is ...

Weight-loss drugs and bariatric surgery both have an impact on cancer risk. A new study breaks down the link and how GLP-1 ...

New animal research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment ...

Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic ...

New animal research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment ...